Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-18-025965
Filing Date
2018-04-24
Accepted
2018-04-24 16:52:10
Documents
2
Period of Report
2018-04-20

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2221
2 POA DOCUMENT poa.txt EX-24.3_784856 3503
  Complete submission text file 0001209191-18-025965.txt   7368
Mailing Address 315 MADISON AVENUE 4TH FLOOR NEW YORK NY 10017
Business Address 315 MADISON AVENUE 4TH FLOOR NEW YORK NY 10017 (813) 864-4523
SELLAS Life Sciences Group, Inc. (Issuer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address 315 MADISON AVE NEW YORK NY 10017
Business Address
Mack Gene (Reporting) CIK: 0001737979 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-33958 | Film No.: 18771937